Literature DB >> 25567133

The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution.

N Puig1, I Conde1, C Jiménez1, M E Sarasquete1, A Balanzategui1, M Alcoceba1, J Quintero2, M C Chillón1, E Sebastián1, R Corral1, L Marín1, N C Gutiérrez1, M-V Mateos1, M González-Díaz1, J F San-Miguel3, R García-Sanz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25567133     DOI： 10.1038/leu.2015.7

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.

Authors:  María Eugenia Sarasquete; Ramón García-Sanz; David González; Joaquín Martínez; Gema Mateo; Pilar Martínez; José Maria Ribera; José Mariano Hernández; Juan José Lahuerta; Alberto Orfão; Marcos González; Jesus F San Miguel
Journal:  Haematologica       Date:  2005-10       Impact factor: 9.941

2.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

3.  Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma.

Authors:  Niklas Zojer; Heinz Ludwig; Michael Fiegl; Freda K Stevenson; Surinder S Sahota
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

4.  Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene.

Authors:  Q M Ralph; M J Brisco; D E Joshua; R Brown; J Gibson; A A Morley
Journal:  Blood       Date:  1993-07-01       Impact factor: 22.113

5.  Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin.

Authors:  A Beishuizen; K Hählen; A Hagemeijer; M A Verhoeven; H Hooijkaas; H J Adriaansen; I L Wolvers-Tettero; E R van Wering; J J van Dongen
Journal:  Leukemia       Date:  1991-08       Impact factor: 11.528

6.  Clonal selection in acute lymphoblastic leukaemia demonstrated by polymerase chain reaction analysis of immunoglobulin heavy chain and T-cell receptor delta chain rearrangements.

Authors:  K Langlands; J I Craig; R S Anthony; A C Parker
Journal:  Leukemia       Date:  1993-07       Impact factor: 11.528

Review 7.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Authors:  J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

8.  SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status.

Authors:  L López-Corral; M E Sarasquete; S Beà; R García-Sanz; M V Mateos; L A Corchete; J M Sayagués; E M García; J Bladé; A Oriol; M T Hernández-García; P Giraldo; J Hernández; M González; J M Hernández-Rivas; J F San Miguel; N C Gutiérrez
Journal:  Leukemia       Date:  2012-05-08       Impact factor: 11.528

9.  Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Authors:  Laura Rosiñol; Albert Oriol; Ana Isabel Teruel; Dolores Hernández; Javier López-Jiménez; Javier de la Rubia; Miquel Granell; Joan Besalduch; Luis Palomera; Yolanda González; María Asunción Etxebeste; Joaquín Díaz-Mediavilla; Miguel T Hernández; Felipe de Arriba; Norma C Gutiérrez; María Luisa Martín-Ramos; María Teresa Cibeira; María Victoria Mateos; Joaquín Martínez; Adrián Alegre; Juan José Lahuerta; Jesús San Miguel; Joan Bladé
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113

10.  Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.

Authors:  Joaquin Martinez-Lopez; Juan J Lahuerta; François Pepin; Marcos González; Santiago Barrio; Rosa Ayala; Noemí Puig; María A Montalban; Bruno Paiva; Li Weng; Cristina Jiménez; María Sopena; Martin Moorhead; Teresa Cedena; Immaculada Rapado; María Victoria Mateos; Laura Rosiñol; Albert Oriol; María J Blanchard; Rafael Martínez; Joan Bladé; Jesús San Miguel; Malek Faham; Ramón García-Sanz
Journal:  Blood       Date:  2014-03-19       Impact factor: 22.113
View more
  4 in total

Review 1.  Monitoring minimal residual disease in the bone marrow using next generation sequencing.

Authors:  Even H Rustad; Eileen M Boyle
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-17       Impact factor: 3.020

2.  Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses.

Authors:  Qiumei Yao; Gareth J Morgan; Chor Sang Chim
Journal:  Clin Epigenetics       Date:  2018-12-20       Impact factor: 6.551

3.  Timing the initiation of multiple myeloma.

Authors:  Even H Rustad; Venkata Yellapantula; Daniel Leongamornlert; Niccolò Bolli; Guy Ledergor; Ferran Nadeu; Nicos Angelopoulos; Kevin J Dawson; Thomas J Mitchell; Robert J Osborne; Bachisio Ziccheddu; Cristiana Carniti; Vittorio Montefusco; Paolo Corradini; Kenneth C Anderson; Philippe Moreau; Elli Papaemmanuil; Ludmil B Alexandrov; Xose S Puente; Elias Campo; Reiner Siebert; Herve Avet-Loiseau; Ola Landgren; Nikhil Munshi; Peter J Campbell; Francesco Maura
Journal:  Nat Commun       Date:  2020-04-21       Impact factor: 14.919

4.  Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.

Authors:  Alejandro Medina; Noemi Puig; Juan Flores-Montero; Cristina Jimenez; M-Eugenia Sarasquete; María Garcia-Alvarez; Isabel Prieto-Conde; Carmen Chillon; Miguel Alcoceba; Norma C Gutierrez; Albert Oriol; Laura Rosinol; Joan Bladè; Mercedes Gironella; Miguel T Hernandez; Veronica Gonzalez-Calle; Maria-Teresa Cedena; Bruno Paiva; Jesus F San-Miguel; Juan-Jose Lahuerta; Maria-Victoria Mateos; Joaquin Martinez-Lopez; Alberto Orfao; Marcos Gonzalez; Ramon Garcia-Sanz
Journal:  Blood Cancer J       Date:  2020-10-30       Impact factor: 11.037
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.